InMed Pharmaceuticals Makes Progress on Alzheimer’s Drug

InMed Pharmaceuticals (INM) has released an update.

InMed Pharmaceuticals has made significant strides in its pharmaceutical programs, particularly with its Alzheimer’s treatment candidate, INM-901, showing promising preclinical data. The company also executed a reverse stock split to ensure continued compliance with Nasdaq listing requirements, reflecting its commitment to enhancing shareholder value.

For further insights into INM stock, check out TipRanks’ Stock Analysis page.